NEW YORK--(BUSINESS WIRE)--
Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biosciences and
clinical laboratory company, announced today the appointment of James M.
O’Brien as Senior Vice President, Finance.
“Jim has an impressive professional background and brings over 15 years
of experience leading and managing all financial functions for a number
of diverse global organizations. Jim has held leadership positions in
the areas of planning and strategic development, financial analysis, SEC
reporting and internal controls for both large and small multi-national
public companies,” said Barry Weiner, President of Enzo Biochem, Inc.
“We are excited that Jim has joined our team and we look forward to his
input and assistance in strengthening and adding value to our Company.”
Most recently Mr. O’Brien was Vice President and Corporate Controller
for Actavis, plc., (NYSE:ACT) a multi-billion global specialty
pharmaceutical company. Previously, he held senior level finance
positions with Nycomed US, Aptuit, Inc., Purdue Pharma LLP and Bristol
Myers Squibb Company. Mr. O’Brien began his career in public accounting
with PricewaterhouseCoopers LLP. He holds a BA from George Washington
University and an MBA in Finance from Fordham University. Jim achieved
his CPA in 1992.
Separately, Mr. Weiner also commented on the recent departures of Andrew
Crescenzo, who Mr. O’Brien succeeds, and Andrew Whiteley, formerly COO
of Enzo Life Sciences. “We appreciate the contributions and years of
service that both Drew and Andrew provided to the Company, and we wish
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and therapeutics
through the development of unique diagnostic platform technologies that
provide numerous advantages over previous standards. A global company,
Enzo Biochem utilizes cross-functional teams to develop and deploy
products systems and services that meet the ever-changing and rapidly
growing needs of health care both today and into the future.
Underpinning Enzo Biochem’s products and technologies is a broad and
deep intellectual property portfolio, with patent coverage across a
number of key enabling technologies.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management, including those related
to cash flow, gross margins, revenues, and expenses are dependent on a
number of factors outside of the control of the company including, inter
alia, the markets for the Company’s products and services, costs of
goods and services, other expenses, government regulations, litigations,
and general business conditions. See Risk Factors in the Company’s Form
10-K for the fiscal year ended July 31, 2013. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
For Enzo Biochem, Inc.
Anreder & Company
Michael Wachs, 212-732-4300
Source: Enzo Biochem, Inc.